Mechanism of Action and Synthesis of Mezlocillin

Mezlocillin is an extended-spectrum, semisynthetic ureidopenicillin antibiotic. Overview & Mechanism • Class: Extended-spectrum beta-lactam penicillin/acylureido. • Mechanism: Produces a bactericidal action by preventing the formation of bacterial cell walls. • Spectrum: Effective against a variety of anaerobic bacteria (such as Bacteroides fragilis), Gram-negative bacilli (such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella, and Proteus), and Gram-positive cocci (such as streptococci and enterococci). Pharmacokinetics • Administration: Intramuscular (IM) or intravenous (IV) injection (poorly absorbed orally). • Half-life: 60–66 minutes, or around 0.7–1.1 hours. • Excretion: Mainly removed via biliary excretion and the kidneys (urine). • The range of protein binding is 16% to 42%. Clinical Indications · Infections of the lower respiratory tract · UTIs, or urinary tract infections · Infections of the skin and skin structure · Peritonitis and intra-abdominal infections · Infections related to gynecology · Infections of the bones and joints (osteomyelitis) · Bacteremia or septicemia

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-05
DOI
https://doi.org/10.5281/zenodo.23970244
Primary Topic
Synthesis of β-Lactam Compounds
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mechanism of Action and Synthesis of Mezlocillin

Yerikala Ramesh, Muralinath E.
Zenodo (CERN European Organization for Nuclear Research)
Synthesis of β-Lactam Compounds
article

Mechanism of Action and Synthesis of Mezlocillin

Yerikala Ramesh, Muralinath E.
article en

Abstract

Mezlocillin is an extended-spectrum, semisynthetic ureidopenicillin antibiotic. Overview & Mechanism • Class: Extended-spectrum beta-lactam penicillin/acylureido. • Mechanism: Produces a bactericidal action by preventing the formation of bacterial cell walls. • Spectrum: Effective against a variety of anaerobic bacteria (such as Bacteroides fragilis), Gram-negative bacilli (such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella, and Proteus), and Gram-positive cocci (such as streptococci and enterococci). Pharmacokinetics • Administration: Intramuscular (IM) or intravenous (IV) injection (poorly absorbed orally). • Half-life: 60–66 minutes, or around 0.7–1.1 hours. • Excretion: Mainly removed via biliary excretion and the kidneys (urine). • The range of protein binding is 16% to 42%. Clinical Indications · Infections of the lower respiratory tract · UTIs, or urinary tract infections · Infections of the skin and skin structure · Peritonitis and intra-abdominal infections · Infections related to gynecology · Infections of the bones and joints (osteomyelitis) · Bacteremia or septicemia

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 27%
Synthesis of β-Lactam Compounds
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon